All In MedTech

FDA Clearance Tracker · P250009

SQUID Liquid Embolic Agent (LEA)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jan 30, 2026

Approved

Time to decision

315 days

Received Mar 21, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250009
Device name
SQUID Liquid Embolic Agent (LEA)
Applicant
Balt USA, LLC
Applicant location
Irvine, CA
Received
Mar 21, 2025
Decided
Jan 30, 2026
Decision
Approved
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SGU

FDA's approval statement

As written in FDA's record.

The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness in whom an intervention is deemed necessary as determined by a neurosurgeon.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code SGU. The earliest in FDA's data is P030004-S035, decided Dec 8, 2025.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Balt USA, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.